Scientists build a biobank to decode ARDS and personalize treatment

NCT ID NCT07675265

Not yet recruiting Knowledge-focused Sponsor: Prenosis, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study collects blood samples and health data from 1,200 adults with ARDS in intensive care. Researchers aim to identify biological markers that can group patients into subtypes and predict how they will respond to different treatments. The goal is to improve care for this life-threatening lung condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better ways to classify ARDS subtypes and predict which treatments work best for individual patients.

What could go wrong

This is an observational study, not a treatment trial. The algorithms developed may not prove accurate enough for clinical use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME)